These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 26740636

  • 1. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J.
    Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
    [Abstract] [Full Text] [Related]

  • 2. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I.
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [Abstract] [Full Text] [Related]

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 4. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
    Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH.
    Ann Intern Med; 2016 Jun 07; 164(11):705-14. PubMed ID: 27110660
    [Abstract] [Full Text] [Related]

  • 5. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM.
    Int J Cardiol; 2016 Oct 01; 220():14-20. PubMed ID: 27389437
    [Abstract] [Full Text] [Related]

  • 6. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
    Toh S, Reichman ME, Graham DJ, Hampp C, Zhang R, Butler MG, Iyer A, Rucker M, Pimentel M, Hamilton J, Lendle S, Fireman BH, Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group.
    Diabetes Care; 2018 Jan 01; 41(1):39-48. PubMed ID: 29122893
    [Abstract] [Full Text] [Related]

  • 7. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
    Farr AM, Sheehan JJ, Brouillette M, Smith DM, Johnston SS, Kalsekar I.
    Adv Ther; 2016 Jan 01; 33(1):68-81. PubMed ID: 26724938
    [Abstract] [Full Text] [Related]

  • 8. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.
    Circulation; 2019 Jun 18; 139(25):2822-2830. PubMed ID: 30955357
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL, Hsiao FY, Chiang CK, Shen LJ, Huang CF.
    PLoS One; 2019 Jun 18; 14(5):e0215248. PubMed ID: 31112536
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
    Fadini GP, Saragoni S, Russo P, Degli Esposti L, Vigili de Kreutzenberg S, Melazzini M, Avogaro A, OsMed Health DB Network.
    Diabetes Obes Metab; 2017 Oct 18; 19(10):1416-1424. PubMed ID: 28432754
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL, Worley K, Meah Y, Everhart D.
    J Manag Care Spec Pharm; 2017 Mar 18; 23(3):299-306. PubMed ID: 28230454
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.